科研成果：科学论文与知识产权

专注给予质高价优

的生物药

科学论文

Identification of novel KAT6A/B inhibitors with enhanced antitumor activity and reduced hematologic toxicity
AACR 2025
A novel anti-PD-L1/VEGF bispecific antibody (HLX37) with immune checkpoint inhibition, anti-angiogenic, and antineoplastic activities
AACR 2025
HLX22 plus trastuzumab and XELOX for first-line treatment of HER2-positive locally advanced or metastatic gastric/gastroesophageal junction cancer (G/GEJC): Updated results with additional patients
ASCO GI 2025
Ren Z, Shao G, Shen J, et al. Serplulimab-HCC Investigators. Phase 2 study of serplulimab with the bevacizumab biosimilar HLX04 in the first-line treatment of advanced hepatocellular carcinoma. Cancer Immunol Immunother. 2025 Jan 3;74(2):69. doi: 10.1007/s00262-024-03917-w. PMID: 39751879; PMCID: PMC11699032.
Cancer Immunology, Immunotherapy
Updated efficacy and subgroup analysis of first-line serplulimab plus bevacizumab and XELOX versus placebo plus bevacizumab and XELOX in metastatic colorectal cancer: a phase 2/3 study
ASCO GI 2025
Safety and Efficacy of Perioperative Chemotherapy Combined with PD-1 Inhibitor versus Chemotherapy with D2 plus Gastrectomy and PAND in Gastric Cancer with PAN Metastasis: A Single-Center Retrospective Cohort Study
ASCO GI 2025

知识产权

专利申请数量	PCT申请数量	国内外授权专利数量	注册司法权区	申请日期	到期日	发明专利数量
809	90	134	中国大陆	2011-03-18	2031-03-18	97

304am永利